Economic Evaluation of FebriDx®: A Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States
**Background:** Acute respiratory infections (ARIs) are commonly treated with antibiotics in outpatient settings, but many infections are caused by viruses and antibiotic treatment is therefore inappropriate. FebriDx®, a rapid point-of-care test that can differentiate viral from bacterial infections...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2021-09-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.27753 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860320280510464 |
|---|---|
| author | Katherine Dick John Schneider |
| author_facet | Katherine Dick John Schneider |
| author_sort | Katherine Dick |
| collection | DOAJ |
| description | **Background:** Acute respiratory infections (ARIs) are commonly treated with antibiotics in outpatient settings, but many infections are caused by viruses and antibiotic treatment is therefore inappropriate. FebriDx®, a rapid point-of-care test that can differentiate viral from bacterial infections, can inform antibiotic treatment decisions.
**Objectives:** The primary aim of this study is to conduct a literature-based US economic evaluation of a novel rapid point-of-care test, FebriDx®, that simultaneously measures two key infection biomarkers, C-reactive protein (CRP) and\ Myxovirus resistance protein A (MxA), to accurately differentiate viral from bacterial infection.
**Methods:** A budget impact model was developed based on a review of published literature on antibiotic prescribing for ARIs in the United States. The model considers the cost of antibiotic treatment, antibiotic resistant infections, antibiotic-related adverse events, and point-of-care testing. These costs were extrapolated to estimate savings on a national level.
**Results:** The expected national cost to treat ARIs under standard of care was US \$8.25 billion, whereas the expected national cost of FebriDx point-of-care-guided ARI treatment was US \$5.74 billion. Therefore, the expected national savings associated with FebriDx® rapid point-of-care testing was US \$2.51 billion annually.
**Conclusions:** FebriDx, a point of care test that can reliably aid in the differentiation of viral and bacterial infections, can reduce antibiotic misuse and, therefore, antibiotic resistant infections. This results in significant cost savings, driven primarily by the reduction in antibiotic resistant infections. |
| format | Article |
| id | doaj-art-fdb152b165f94ccab4edb34881a4e6fd |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2021-09-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-fdb152b165f94ccab4edb34881a4e6fd2025-02-10T16:13:08ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362021-09-0182Economic Evaluation of FebriDx®: A Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United StatesKatherine DickJohn Schneider**Background:** Acute respiratory infections (ARIs) are commonly treated with antibiotics in outpatient settings, but many infections are caused by viruses and antibiotic treatment is therefore inappropriate. FebriDx®, a rapid point-of-care test that can differentiate viral from bacterial infections, can inform antibiotic treatment decisions. **Objectives:** The primary aim of this study is to conduct a literature-based US economic evaluation of a novel rapid point-of-care test, FebriDx®, that simultaneously measures two key infection biomarkers, C-reactive protein (CRP) and\ Myxovirus resistance protein A (MxA), to accurately differentiate viral from bacterial infection. **Methods:** A budget impact model was developed based on a review of published literature on antibiotic prescribing for ARIs in the United States. The model considers the cost of antibiotic treatment, antibiotic resistant infections, antibiotic-related adverse events, and point-of-care testing. These costs were extrapolated to estimate savings on a national level. **Results:** The expected national cost to treat ARIs under standard of care was US \$8.25 billion, whereas the expected national cost of FebriDx point-of-care-guided ARI treatment was US \$5.74 billion. Therefore, the expected national savings associated with FebriDx® rapid point-of-care testing was US \$2.51 billion annually. **Conclusions:** FebriDx, a point of care test that can reliably aid in the differentiation of viral and bacterial infections, can reduce antibiotic misuse and, therefore, antibiotic resistant infections. This results in significant cost savings, driven primarily by the reduction in antibiotic resistant infections.https://doi.org/10.36469/001c.27753 |
| spellingShingle | Katherine Dick John Schneider Economic Evaluation of FebriDx®: A Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States Journal of Health Economics and Outcomes Research |
| title | Economic Evaluation of FebriDx®: A Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States |
| title_full | Economic Evaluation of FebriDx®: A Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States |
| title_fullStr | Economic Evaluation of FebriDx®: A Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States |
| title_full_unstemmed | Economic Evaluation of FebriDx®: A Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States |
| title_short | Economic Evaluation of FebriDx®: A Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States |
| title_sort | economic evaluation of febridx r a novel rapid point of care test for differentiation of viral versus bacterial acute respiratory infection in the united states |
| url | https://doi.org/10.36469/001c.27753 |
| work_keys_str_mv | AT katherinedick economicevaluationoffebridxanovelrapidpointofcaretestfordifferentiationofviralversusbacterialacuterespiratoryinfectionintheunitedstates AT johnschneider economicevaluationoffebridxanovelrapidpointofcaretestfordifferentiationofviralversusbacterialacuterespiratoryinfectionintheunitedstates |